Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 4/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330351 | 0.80 | PDPK1 (0.44) | KDM4EHTTUTS2RPRKCIMAPT | |
| SCHEMBL4159284 | 0.78 | KDM4E (0.38) | KDM4ETP53HSP90AA1HTTSMN1; SMN2 | |
| SCHEMBL14830510 | 0.76 | EPHB4 (0.32) | KDM4ETP53HSP90AA1HTTSMN1; SMN2 | |
| SCHEMBL16515634 | 0.74 | KDM4E (0.45) | KDM4ETP53SMN1; SMN2KMT2ATDP1 | |
| SCHEMBL31337031 | 0.71 | MAPK1 (0.33) | GPR35NPC1 | |
| SCHEMBL23104538 | 0.71 | PDPK1 (0.43) | UTS2RPRKCIGPR35NPC1CYP1A2 | |
| SCHEMBL30401622 | 0.68 | GPR35 (0.31) | GPR35 | |
| SCHEMBL26970098 | 0.68 | KDM4E (0.34) | KDM4ETP53HSP90AA1HTTSMN1; SMN2 | |
| SCHEMBL25169268 | 0.68 | GPR35 (0.31) | GPR35 | |
| SCHEMBL3234401 | 0.67 | TSHR (0.50) | KDM4ETP53HSP90AA1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| EP-1730145-A1 | ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| WO-2005095401-A1 | ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | NR3C1, NR3C2, MC2R | KDM4E 3591/4885TP53 817/4885HSP90AA1 2261/4885 |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, MC2R, NR3C2 | KDM4E 3760/4885TP53 898/4885HSP90AA1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.